Results 91 to 100 of about 6,491 (191)

Neutralizing epitopes of RSV and palivizumab resistance in Japan [PDF]

Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower respiratory infection in young children. The virus surface envelope contains the G, F, and SH proteins as spike proteins.
Hashimoto, Koichi, Hosoya, Mitsuaki
core  

Palivizumab for preterm infants. Is it worth it?

Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is uncertain whether the cost is justified.
Harkensee C, Embleton ND, Mckean MC
core   +2 more sources

Development and validation of an enzyme linked immunosorbent assay for palivizumab serum determination.

, 2013
Palivizumab (Synagis) is a humanized monoclonal antibody (IgG1K) composed of 95 percent human and 5 percent murine sequences. It is directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
Ragazzi M., BLOISE, NORA, Montagna M, Avanzini MA, Di Comite A, Iommiello V, VISAI, LIVIA, Stronati M   +7 more
core  

Adjunctive palivizumab with ribavirin for respiratory syncytial virus infection during the early peri-transplant period in adult allogenic hematopoietic stem cell transplant recipients: Case series. [PDF]

IDCases
Aleshaiwi L, Alotaibi A, Alzahrani M, Bosaeed M, AlQahtani H, Almohaya A.   +5 more
europepmc   +1 more source

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

, 2008
Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV ...
Octavio Ramilo, Asunción Mejías   +1 more
core  

Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review. [PDF]

Hum Vaccin Immunother
Razzini JL, Martinon-Torres F.
europepmc   +1 more source

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database. [PDF]

Kans J Med
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +1 more source

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. [PDF]

Vaccines (Basel)
Paes BA, Manzoni P, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X.   +4 more
europepmc   +1 more source

Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab

Background: Palivizumab is one of the most costly paediatric medications for Medicaid and other health plans. It is uncertain whether the costs of palivizumab administration are justified in specific risk groups.
John Feaganes, Steven Wegner, Julie Jacobson Vann   +2 more
core  

Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025. [PDF]

Hosp Pediatr
Teoh Z, Tannis A, Sullivan E, Boom JA, Halasa N, Michaels MG, Payne DC, Sahni LC, Schuster J, Selvarangan R, Staat MA, Stewart LS, Szilagyi PG, Weinberg GA, Williams JV, Dawood FS, Klein EJ, Moline H, Englund JA, Zerr DM.   +19 more
europepmc   +1 more source